CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


AbataceptWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2366 Streptokinase Wiki 1.00
drug2595 Unfractionated heparin Wiki 0.71
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

NCT04472494 COVID-19 SARS-CoV-2 Biological: Abatacept Other: Placebo

Primary Outcomes

Measure: Proportion of participants with composite end point of mechanical ventilation or death prior to or on Day 28

Time: Up to 28 days

Secondary Outcomes

Measure: Change from baseline in the Ordinal 8-point Outcome Scale on Day 28

Time: Day 28

Measure: All-cause mortality on Day 28

Time: Day 28

Measure: Proportion of participants alive and free of respiratory failure on Day 28

Time: Day 28

Measure: Proportion of participants returned to room air by Day 28

Time: Up to 28 days

Measure: Proportion of participants alive and discharged home by Day 28

Time: Up to 28 days

Measure: Proportion of participants with Serious Adverse Events (SAEs)

Time: Up to 60 days

Measure: Proportion of participants with serious infections

Time: Up to 60 days


No related HPO nodes (Using clinical trials)